Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esreboxetine - Axsome Therapeutics

Next Previous
X
Search
Drug Profile

Esreboxetine - Axsome Therapeutics

Alternative Names: [S,S]-Reboxetine; AXS-14; PNU-165442G

Latest Information Update: 09 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Axsome Therapeutics; Pfizer
  • Class Antidepressants; Morpholines; Small molecules; Urologics
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fibromyalgia
  • Discontinued Diabetic neuropathies; Major depressive disorder; Postherpetic neuralgia; Stress incontinence

Most Recent Events

  • 05 Aug 2024 Axsome Therapeutics announces intention to submit NDA to the US FDA for Fibromyalgia in the third quarter of 2024
  • 27 Sep 2022 Esreboxetine is still in phase III clinical trials in Fibromyalgia in USA (PO) (Axsome Therapeutics website, September 2022)
  • 10 May 2021 Axsome Therapeutics met the US FDA for clinical development of esreboxetine for fibromyalgia, before May 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top